Effectiveness modelling and economic evaluation of primary HPV screening for cervical cancer prevention in New Zealand

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Lew, Jie Bin ^a   Simms, Kate ^a   Smith, Megan ^a   Lewis, Hazel ^b   Neal, Harold ^c   Canfell, Karen ^a,d  

^a CANCER RESEARCH DIVISION   (Australia)

^b Public Health Physician   (New Zealand)

^c MINISTRY OF HEALTH   (New Zealand)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CALIBRATION; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; ECONOMIC EVALUATION; FEMALE; GENOTYPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; NEW ZEALAND; PRECANCER; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS TRANSMISSION; WART VIRUS; ALPHAPAPILLOMAVIRUS; ECONOMICS; ISOLATION AND PURIFICATION; MASS SCREENING; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADULT; ALPHAPAPILLOMAVIRUS; FEMALE; HEALTH CARE COSTS; HUMANS; MASS SCREENING; MODELS, ORGANIZATIONAL; NEW ZEALAND; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84969257662     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151619     Document Type: Article

References (51)

1. National Screening Unit (2008) Guidelines for Cervical Screening in New Zealand: Incorporating the management of women with abnormal cervical smears. Wellington: National Screening Unit, Ministry of Health.
2. Ministry of Health (2014) History of the HPV immunisation programme. Available: http://www.health. govt.nz/our-work/preventative-health-wellness/immunisation/hpv-immunisation-programme/historyhpv-immunisation-programme. Accessed 23 September 2015.
3. Ministry of Health (2014) HPV immunisation programme. [updated 27 June 2014] Available: http:// www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-immunisationprogramme. Accessed 17 February 2015.
4. Elfstrom KM, Smelov V, Johansson AL, Eklund C, Naucler P, Arnheim-Dahlstrom L, et al. (2014) Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. Bmj 348: g130. doi: 10.1136/bmj.g130 PMID: 24435414
5. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla PP, Del MA, et al. (2010) Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 11: 249-257. doi: 10.1016/S1470-2045(09)70360-2 PMID: 20089449
6. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. (2011) A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial. Eur J Cancer 47: 864-871. doi: 10.1016/j.ejca.2011.01.008 PMID: 21334200
7. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. Bmj 337: a1754. doi: 10.1136/bmj.a1754 PMID: 18852164
8. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. (2014) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383: 524-532. doi: 10.1016/S0140-6736(13)62218-7 PMID: 24192252
9. Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. (2014) The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 18: 1-196.
10. Lew JB, Simms K, Smith MA, Kang YK, Xu XM, Caruana M, et al. (2014) National Cervical Screening Program Renewal: Effectiveness modelling and economic evaluation in the Australian setting (Assessment Report). MSAC application number 1276. Canberra: Department of Health
11. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ (2012) Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 106: 1571-1578. doi: 10. 1038/bjc.2012.94 PMID: 22441643
12. National Institute for Public Health and the Environment MoH, Welfare and Sport. (2014) Cervical cancer screening in the Netherlands. [updated 21/01/2014] Available: http://www.rivm.nl/en/Documents- and-publications/Common-and-Present/Newsmessages/2014/Cervical-cancer-screening-in-the- Netherlands. Accessed 21 January 2015.
13. Ministero della Salute (2014) Piano Nazionale di Prevenzione 2014-2018. Available: http://www. salute.gov.it/imgs/C-17-pubblicazioni-2285-allegato.pdf. Accessed 12/02/2016
14. Australian Government Department of Health (2014) National Cervical Screening Program Renewal. [updated 15/5/2014] Available: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/ Content/overview-of-the-renewal. Accessed 21 January 2015 2015.
15. Creighton P, Lew JB, Clements M, Smith M, Howard K, Dyer S, et al. (2010) Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health 10: 734. doi: 10.1186/1471-2458-10-734 PMID: 21110881
16. Canfell K, Barnabas R, Patnick J, Beral V (2004) The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 91: 530-536. PMID: 15266332
17. Medical Services Advisory Committee (2009) Automation Assisted and Liquid Based Cytology for Cervical Cancer Screening. MSAC reference 1122, Assessment report. Canberra: Australian Government Department of Health.
18. Medical Services Advisory Committee (2009) Human Papillomavirus Triage Test For Women With Possible or Definite Low-Grade Squamous Intraepithelial Lesions. MSAC reference 39, Assessment report. Canberra: Australian Government Department of Health.
19. Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, et al. (2011) Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 29: 2487-2494. doi: 10.1016/j.vaccine.2010.12.085 PMID: 21211586
20. Legood R, Smith MA, Lew JB, Walker R, Moss S, Kitchener H, et al. (2012) Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. BMJ 345.
21. Lew J-B, Howard K, Gertig D, Smith M, Clements M, Nickson C, et al. (2012) Expenditure and resource utilisation for cervical screening in Australia. BMC Health Services Research 12: 446. doi: 10.1186/ 1472-6963-12-446 PMID: 23216968
22. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV (2008) The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 123: 1854-1863. doi: 10.1002/ijc.23633 PMID: 18636563
23. Smith MA, Canfell K (2014) Incremental benefits of male HPV vaccination: Accounting for inequality in population uptake. PLoS One 9.
24. Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, et al. (2011) Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 9: 104. doi: 10.1186/1741-7015-9-104 PMID: 21910918
25. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, et al. (2006) HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95: 56-61. PMID: 16773068
26. Simonella L, Lewis H, Smith M, Neal H, Bromhead C, Canfell K (2013) The prevalence of type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infect Dis 13.
27. Sykes P, Gopala K, Tan AL, Kenwright D, Petrich S, Molijn A, et al. (2014) Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand. BMC Infect Dis 14: 374. doi: 10.1186/1471-2334-14-374 PMID: 25000939
28. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2009) A review of human carcinogens. Part B: Biological agents. Chapter 11: Human Papillomaviruses. Lyon, France: IARC.
29. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. (2008) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncology 9: 425-434. doi: 10.1016/S1470-2045(08)70103-7 PMID: 18407790
30. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J (2008) Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstetrics & Gynecology 111: 167-177.
31. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. (2012) Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 Suppl 5: F88-99. doi: 10.1016/j.vaccine.2012.06.095 PMID: 23199969
32. Smith M, Walker R, Canfell K (2013) National Cervical Screening Programme Monitoring Report Number 37. Wellington, NZ: National Screening Unit.
33. Smith M, Walker R, Canfell K (2014) National Cervical Screening Programme Monitoring Report Number 38. Wellington, NZ: National Screening Unit.
34. Smith M, Walker R, Canfell K (2014) National Cervical Screening Programme Monitoring Report Number 39. Wellington, NZ: National Screening Unit.
35. Smith M, Walker R, Canfell K (2014) National Cervical Screening Programme Monitoring Report Number 40. Wellington, NZ: National Screening Unit.
36. Ministry of Health (2011) The Price of Cancer: The public price of registered cancer in New Zealand. Wellington: Ministry of Health.
37. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M (2001) Age standardization of rates: A new WHO standard. Geneva: World Health Organization.
38. Statistics New Zealand (2013) National population projections: 2011(base) -2061. Available: http:// nzdotstat.stats.govt.nz/wbos/Index.aspx. Accessed 15 October 2013.
39. Smith M, Walker R, Canfell K (2013) National Cervical Screening Programme Annual Report (2010-2011). Wellington, NZ: National Screening Unit.
40. Ministry of Health (2012) Cancer: New registrations and deaths 2009. Wellington: Ministry of Health.
41. Ministry of Health (2011) Cancer: New registrations and deaths 2008. Wellington, New Zealand: Ministry of Health.
42. Ministry of Health (2014) Cancer: New registrations and deaths 2011. Wellington: Ministry of Health.
43. Ministry of Health (2010) Cancer: New registrations and deaths 2007. Wellington: Ministry of Health.
44. Ministry of Health (2010) Cancer: New registrations and deaths 2006. Wellington: Ministry of Health.
45. Ministry of Health (2009) Cancer: New Registrations and Deaths 2005 Revised edition. Wellington, New Zealand: Ministry of Health.
46. Ministry of Health (2013) Cancer: New Registrations and deaths 2010. Wellington: Ministry of Health.
47. New Zealand Health Information Service (2006) Cancer patient survival: Covering the period 1994-2003. Wellington, New Zealand: Ministry of Health.
48. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370: 890-907. PMID: 17826171
49. Medical Services Advisory Committee (2014) MSAC Outcomes Public Summary Document: Application No. 1276 -Renewal of the National Cervical Screening Program. Available: http://www.msac.gov. au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639CA25799200058940/$File/1276%20-%20Final%20MSAC%20PSD%20-%20NCSP%20Renewal.pdf. Accessed 28 May 2015 2015.
50. Duffy AP, Barrett DK, MA D (1999) Report of the Ministerial Inquiry into the Under-reporting of Cervical Smear Abnormalities in the Gisborne Region. Available: http://www.moh.govt.nz/notebook/nbbooks. nsf/0/a79b9e52f04d57e5cc256a9f006f1687/$FILE/csireport.pdf. Accessed 23 September 2015.
51. Committee of Inquiry into Allegations Concerning the Treatment of Cervical Cancer at National Women's Hospital and into Other Related Matters (1988) The Report of the Cervical Cancer Inquiry 1988. Available: http://www.moh.govt.nz/notebook/nbbooks.nsf/0/64D0EE19BA628E4FCC256E450001CC21/$file/The%20Cartwright%20Inquiry%201988.pdf. Accessed 22 June 2015.